← Back to patent-cliff list
Glumetinib
Tier C — Watch / tradeGlumetinib
-
Originator
2023
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：c-Met
Brand：Haiyitan
Indications (approved)：Non-small cell lung cancer
Regional status
US
Phase II
2019-07-15
EU
-
China
Approved
2023-03-07
Japan
Approved
2024-06-24
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Glumetinib?
Approved indications include: Non-small cell lung cancer.
When does the Glumetinib patent expire?
No public expiry year is available for Glumetinib yet; this page updates once verified.
How do I get a quote for Glumetinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27